Row No	REC No	IRAS No	Submission Type	Name of Trial	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:
1	16/LO/1355	168344	HRA Approval	InPACT trial- International Penile Advanced Cancer Trial (International Rare Cancers Initiative study)		14			16/12/2016	01/12/2017	11/10/2016	14/12/2017	15/12/2017	15/12/2017						Y			Y		It's rare disease but we will be taking referrals regionnally. There is a very long recruitment window	Neither
2	16/LO/1024	195085	HRA Approval	Safety and efficacy of Belimumab After B cell depletion therapy in systemic LUPUS erythematosus		29			11/07/2017	09/01/2018	20/09/2016	21/12/2017	07/02/2018	07/02/2018						Y					strict inclusion criteria	Neither
3	17/EE/0481	226412	HRA Approval	Pre-Implantation Trial of Histopathology In renal Allografts (PITHIA)		15			29/08/2017	23/01/2018	05/01/2018	07/02/2018	07/02/2018	07/02/2018							Y				This is not a typical trial that involves sites being randomised to one of five groups and randomisation will determine the start of recruitment. The earliest for any recruitment to happen is 4 months from the ransomisation (considering the site is randomised to a group 1). In principle it makes impossible to meet the target of 30 days.	Neither
4	18/EM/0045	232426	HRA Approval	Outcome of Balloon Arthroplasty in Irreparable Massive Rotator Cuff Tear		146			03/10/2017	23/01/2018	26/04/2018	18/06/2018	18/06/2018	18/06/2018	Y										Delay in getting NIPAG approval	NHS Provider
5	17/EE/0221	223856	HRA Approval	A Phase 2, 24-week, Randomized, Double-Blind, Placebo-Controlled, Mulitcenter Study, Followed by a 24-Week Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects with Idiopathic Pulmonary Fibrosis	16/05/2018	14	208	222	07/02/2017	06/10/2017	14/09/2017	12/07/2017	20/10/2017	20/10/2017				Y							Unable to contact any patients as still awaiting invitation letter approval). Awaiting amendment to PIS before we can write to new patients. There are 4 patients awaiting to be consented with appointments in February and march. 2 patients scheduled for screening - 1 in August and 1 in October.	Sponsor
6	16/EE/0183	199109	HRA Approval	Efficacy and safety of BI 655064 in patients with active lupus nephritis		0			16/02/2017	20/02/2018	01/07/2016	15/02/2018	20/02/2018	20/02/2018						Y			Y		We do not expect to recruit within 30days. This is a rare disease and even the larger specialist centres took almost 12 months to recruit their first patient.	Neither
7	17/LO/1451	229939	HRA Approval	A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Alone or in Addition to Oral Antidiabetes Drugs (OADs)		0			03/07/2017	20/02/2018	24/01/2018	29/01/2018	20/02/2018	20/02/2018				Y		Y					No patients seen - waiting for approval for PIC sites to be added.	Sponsor
8	17/YH/0432	236091	HRA Approval	A double blind (sponsor open) placebo-controlled, stratified, parallel group study to evaluate the efficacy and safety of repeat doses of GSK3772847 in participants with moderate to severe asthma with allergic fungal airway disease (AFAD).		26			06/10/2017	23/02/2018	19/02/2018	15/03/2018	21/03/2018	21/03/2018						Y					2 Screening Failures	Neither
9	17/EE/0040	222216	HRA Approval	Emergency Cerclage in Twin pregnancies at Imminent Risk of Preterm Birth: an Open-Label Randomised Controlled Trial		1			05/12/2017	26/02/2018	02/03/2017	27/02/2018	27/02/2018	27/02/2018						Y					this is a pilot study examining a rare condition, with a national recruitment target of 30 over 1 year. Our local recruitment target is 1 per year. It is extremely unlikely that we will recruit within the next 30 days, and the study should be exempted from this target.	Neither

Row No	REC No	IRAS No	Submission Type	Name of Trial	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:
10	16/LO/0680	186642	HRA Approval	SMILE: Strategy for Maintenance of HIV suppression with elvitegravir+darunavir/ritonavir in children (PENTA 17). A two-arm, Phase 2/3 multicentre, open-label, randomised study evaluating safety and antiviral effect of current standard antiretroviral therapy compared to elvitegravir (EVG) administered with darunavir/ritonavir (DRV/r) in HIV-1 infected, virologically suppressed paediatric participants.		2			27/11/2017	07/03/2018	28/07/2016	02/03/2018	09/03/2018	09/03/2018					Y					Dr Bandi is on annual leave for 2 weeks so although we?ve identified potential participants we?re unable to screen at present, and therefore it?s unlikely we?ll meet the 30 day recruitment target.	NHS Provider
11	15/EM/0095	166503	HRA Approval	A phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC-1031) with Gemcitabine in patients with metastatic pancreatic carcinoma (ACELARATE: Acelarin first line randomised pancreatic study)		14			01/12/2017	26/03/2018	15/06/2016	04/05/2018	09/04/2018	25/06/2018					Y					The only problem I have for the next week is that Dr Iwuji is away and hasn?t got a clinic this week but other than that I can?t see any problems. Thank you for the email and I look forward to working with you	NHS Provider
12	17/EE/0463	227579	HRA Approval	A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]		28			01/12/2017	03/04/2018	15/02/2018	14/05/2018	01/05/2018	01/05/2018						Y				1 patient consented on 31/05/2018 waiting to be randomised	Neither
13	17/LO/1068	224973	HRA Approval	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE IN ADULT MALE PATIENTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC, PREVIOUSLY UNTREATED, METASTATIC CASTRATE-RESISTANT PROSTATE CANCER	16/04/2018	11	167	178	20/04/2017	20/10/2017	27/07/2017	20/10/2017	31/10/2017	31/10/2017						Y				screening going on strict inclusion criteria	Neither
14	17/YH/0228	222492	HRA Approval	CALM- 2 ? CONTROLLING AND LOWERING BLOOD PRESSURE WITH THE MOBIUSHD?		115			29/03/2018	10/04/2018	05/10/2017	17/06/2018	03/08/2018	03/08/2018	Y			Y						Sponsor Green Light delay	Sponsor
15	16/EM/0322	202096	HRA Approval	A randomised-controlled trial of thrombolytic treatment with tenecteplase for acute ischaemic stroke upon awakening	14/09/2018	99	70	169	01/03/2016	29/03/2018	18/08/2017	05/07/2018	06/07/2018	06/07/2018				Y						Sponsor Green Light delay	Sponsor
16	16/SW/0160	205879	HRA Approval	CHALLENGE-UK: A UK cohort of a Phase III study (CHALLENGE: the Colon Health and Lifelong Exercise Change	28/08/2018	41	126	167	02/02/2018	14/03/2018	06/06/2017	12/04/2018	24/04/2018	24/04/2018						Y				Tight Inclusion Criteria	Neither
17	17/SC/0201	209172	HRA Approval	IP Rollover Study (XRuST): An Open-Label, Rollover Study		7			16/06/2017	26/04/2018	10/07/2017	05/05/2018	03/05/2018	03/05/2018						Y				Tight Inclusion Criteria	Neither

Row No	REC No	IRAS No	Submission Type	Name of Trial	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:
18	17/EM/0412	234907	HRA Approval	An adaptive seamless randomized, double-blind, placebo-controlled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patients	08/05/2018	35	116	151	12/10/2017	08/12/2017	04/12/2017	10/01/2018	12/01/2018	12/01/2018						Y					Tight Inclusion Criteria	Neither
19	17/SC/0533	205320	HRA Approval	A PHASE II STUDY OF ATEZOLIZUMAB WITH RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA WHO ARE NOT CANDIDATES FOR HIGH-DOSE THERAPY.		32			06/03/2018	04/05/2018	31/01/2018	30/05/2018	05/06/2018	05/06/2018						Y					Tight Inclusion Criteria	Neither
20	17/NS/0018	223787	HRA Approval	Female Urgency, Trial of Urodynamics as Routine Evaluation (FUTURE study); a superiority randomised clinical trial to evaluate the effectiveness and cost effectiveness of invasive urodynamic investigations in management of women with refractory overactive bladder symptoms		34			18/01/2018	08/05/2018	11/08/2017	14/06/2018	11/06/2018	11/06/2018							Y				Screen going to no suitable patients	Neither
21	17/LO/1656	229212	HRA Approval	A PHASE III, OPEN-LABEL, MULTICENTER, TWO ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED BRAF WILD-TYPE MELANOMA	09/04/2018	52	88	140	28/09/2017	20/11/2017	14/11/2017	03/01/2018	11/01/2018	11/01/2018						Y					Active screening was going on but no patient interested in consenting	Neither
22	17/LO/2072	209317	HRA Approval	Ways Back to Work. The occupational health management of NHS staff with mental health disorders: a feasibility study.	23/04/2018	79	61	140	15/11/2017	04/12/2017	13/12/2017	21/02/2018	21/02/2018	21/02/2018				Y				Y			Difficult inclusion & Exclution Criteria, Now the study is recruited, Delay in Contract Negotiations. Screening going on now study is recruited	Sponsor
23	16/LO/1677	191232	HRA Approval	Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity A phase II, multi-centre, non-randomised, molecularly stratified trial for NSCLC patients to study tumour heterogeneity using genomic analysis		18			20/09/2016	18/05/2018	13/12/2016	13/06/2018	05/06/2018	05/06/2018						Y					tight Inclusion Criteria(Niche population)	Neither
24	17/SS/0052	196827	HRA Approval	Early Valve Replacement guided by Biomarkers of Left Ventricular Decompensation in Asymptomatic Patients with Severe Aortic Stenosis	03/05/2018	41	93	134	04/07/2017	20/12/2017	17/06/2017	03/01/2018	30/01/2018	30/01/2018							Y				Screening going 2 patient consented but Ineligible - criteria failure / pre-screening failure	Neither
25	17/SC/0615	233555	HRA Approval	A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-related Genes (including BRCA1/2)		29			02/02/2018	22/05/2018	16/03/2018	06/06/2018	20/06/2018	20/06/2018						Y					Tight Inclusion Criteria	Neither

Row No	REC No	IRAS No	Submission Type	Name of Trial	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:
26	17/EE/0317	230053	HRA Approval	A Phase 1, Open-Label, Multicentre, Non-Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD4573, a Potent and Selective CDK9 Inhibitor, in Subjects with Relapsed or Refractory Haematological Malignancies		72			13/11/2017	04/06/2018	27/09/2017	03/04/2018	15/08/2018	15/08/2018	Y										Delay in getting ARSAC approval	Neither
27	17/SW/0221	232448	HRA Approval	A randomized, partially-blinded, active-controlled,multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in patients with active ankylosing spondylitis		11			05/04/2018	07/06/2018	28/11/2017	14/05/2018	18/06/2018	18/06/2018							Y				Overall seven patients have been pre-screened and I understand the stumbling block is that they need to be na?ve to this group of drugs	Neither
28	16/SC/0152	180853	HRA Approval	Prevention Of Post-operative Complications By Using HMG-CoA Reductase Inhibitor In Patients Undergoing Oesophagectomy ? A multicentre, randomised, double blind, placebo controlled trial. (Prevention HARP 2)		21			23/09/2016	12/06/2018	13/10/2016	09/07/2018	03/07/2018	03/07/2018					Y						Staffing issues	NHS Provider
29	16/LO/1979	193891	HRA Approval	A randomised trial of non-Selective versus selective adjuvant Therapy in high risk Apparent sTage 1 Endometrial Cancer (STATEC)		43			29/11/2017	12/06/2018	20/12/2016	26/07/2018	25/07/2018	25/07/2018					Y						Staff availability issues	NHS Provider
30	17/YH/0345	233852	HRA Approval	A phase 3, randomised, multicentre study of subcutaneous vs intravenous administration of daratumumab in subjects with relapsed or refractory multiple myeloma	02/05/2018	60	44	104	03/11/2017	18/01/2018	17/01/2018	15/03/2018	19/03/2018	19/03/2018	Y			Y							Amendment request before approval	Sponsor
31	17/LO/1427	216241	HRA Approval	The effects of Calcium Channel Blockers or Angiotensin converting enzyme inhibitor/Angiotensin Receptor Blocker Therapy on Blood Pressure Variability following acute ischaemic Stroke (CAARBS): A Feasibility Trial	05/03/2018	14	82	96	01/09/2017	29/11/2017	25/09/2017	22/11/2017	13/12/2017	13/12/2017							Y				First patient consented with in 30 days but later screening was failed. Actively screening . One patient is recruited	Neither
32	17/NE/0027	215796	HRA Approval	CReST 2 - Colorectal Endoscopic Stenting Trial 2		87			10/01/2017	26/06/2018	03/04/2017	24/08/2018	21/09/2018	21/09/2018					Y						Delay in allocation of nurse	NHS Provider
33	18/LO/0396	238968	HRA Approval	A PHASE 1B STUDY EVALUATING RO7082859 IN COMBINATION WITH RITUXIMAB (R) OR OBINUTUZUMAB (G) PLUS CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (CHOP) IN PARTICIPANTS WITH RELAPSED REFRACTORY FOLLICULAR LYMPHOMA (R/R FL) OR IN PARTICIPANTS WITH UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA		47			09/02/2018	29/06/2018	16/05/2018	28/06/2018	15/08/2018	15/08/2018	Y										Delay in getting ARSAC approval	Neither

Row No	REC No	IRAS No	Submission Type	Name of Trial	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:
34	17/LO/1672	209107	HRA Approval	Investigating the clinical utility of the MDS Test for the oncogenic activity in nevi suspected of being melanoma	11/07/2018	23	68	91	23/11/2017	11/04/2018	17/04/2018	04/04/2018	04/05/2018	04/05/2018				Y							The reason for the delay in recruiting the first patient for the above study was due to (1) Sponsor delay.	Sponsor
35	18/SC/0222	223737	HRA Approval	NeoCLEAR: Neonatal Champagne Lumbar punctures Every time ? An RCT. A multicentre, randomised controlled 2x2 factorial trial to investigate techniques to increase lumbar puncture success	17/09/2018	80	10	90	21/05/2018	19/06/2018	12/06/2018	17/08/2018	07/09/2018	10/09/2018				Y							Last minute changes in contract by sponsor	Sponsor
36	17/NW/0512	221775	HRA Approval	PETReA: Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma	30/05/2018	52	37	89	09/10/2017	02/03/2018	08/11/2017	30/04/2018	23/04/2018	11/05/2018				Y							Delay in sponsor green light	Sponsor
37	17/LO/0085	216434	HRA Approval	Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects with Dialysis-Dependent Chronic Kidney Disease (DD-CKD) (INNO2VATE ? CONVERSION)	29/05/2018	40	43	83	30/01/2017	07/03/2018	21/02/2017	05/03/2018	16/04/2018	16/04/2018							Y				6 week screening period	Neither
38	16/EM/0380	198726	HRA Approval	A multicentre, randomised trial comparing combination gemcitabine/carboplatin and hydroxychloroquine	17/07/2018	50	28	78	25/07/2017	30/04/2018	09/11/2016	25/06/2018	19/06/2018	19/06/2018	Y							Y			Permission delay due to contracts	Neither
39	17/LO/1865	232414	HRA Approval	Randomized, open label, multicentre study assessing the clinical benefit of isatuximab combined with carflizomib (Kyprolis?) and dexamethasone versus carfilzomib with dexamethasone in patients with relapsed and/or refractory multiple myeloma previously treated with 1 to 3 prior lines.	26/03/2018	4	73	77	09/10/2017	08/01/2018	13/12/2017	10/01/2018	12/01/2018	09/02/2018						Y					Screening going on, No Suitable patients	Neither
40	18/EE/0092	235968	HRA Approval	A randomised, double-blind (sponsor unblind), placebo-controlled, multi-centred phase IIa study to evaluate the safety and efficacy of 13 weeks of once daily oral dosing of the selective androgen receptor modulator (SARM) GSK2881078 in older men and post menopausal women with COPD and muscle weakness, participating in home exercise		18			24/05/2017	16/07/2018	25/05/2018	12/07/2018	03/08/2018	03/08/2018						Y					Screening going on, No Suitable patients	Neither
41	17/EM/0444	235251	HRA Approval	Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas	24/04/2018	12	62	74	24/11/2017	09/02/2018	05/02/2018	19/02/2018	21/02/2018	21/02/2018						Y					Screening going on, No Suitable patients	Neither

Row No	REC No	IRAS No	Submission Type	Name of Trial	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:
42	18/EM/0091	242354	HRA Approval	A Randomized, Double-Blind, Placebo Controlled Study To Evaluate Efficacy And Safety Of NEFECON In Patients With Primary IGA Nephropathy At Risk Of Progressing To End-Stage Renal Disease (NeflgArd)		11			25/08/2017	19/07/2018	04/06/2018	02/07/2018	30/07/2018	30/07/2018						Y					Screening going on, No Suitable patients	Neither
43	18/WA/0154	233884	HRA Approval	WHiTE 8 COPAL: A Randomised Controlled Trial of low dose single antibiotic loaded cement versus high dose dual antibiotic loaded cement in patients receiving a hip hemiarthroplasty after fracture.	01/10/2018	66	7	73	08/05/2018	20/07/2018	10/05/2018	20/08/2018	24/09/2018	24/09/2018	Y							Y			Permission delay due to contracts	Neither
44	17/EE/0177	220722	HRA Approval	A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (SVD) versus bortezomib and dexamethasone (VD) in patients with Relapsed or Refractory Multiple Myeloma (RRMM)	22/03/2018	2	70	72	31/08/2017	09/01/2018	24/07/2017	21/12/2017	11/01/2018	11/01/2018						Y					Screening going on, No Suitable patients	Neither
45	17/SW/0207	231037	HRA Approval	Fractional Flow Reserve Derived from Computed Tomography Coronary Angiography in the Assessment and Management of Stable Chest Pain.	17/05/2018	54	17	71	03/10/2017	07/03/2018	03/10/2017	10/04/2018	30/04/2018	01/05/2018	Y							Y			Permission delay due to contracts	Neither
46	17/SC/0070	215616	HRA Approval	RCT The Prepare Multi-Morbid Older People for End-stage Kidney Disease Trial	10/08/2018	15	52	67	17/04/2018	04/06/2018	30/05/2017	06/06/2018	19/06/2018	19/06/2018												Please Select...
47	17/LO/1468	230232	HRA Approval	A phase II, multicenter, open-label, two-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment		30			22/01/2018	25/07/2018	13/11/2017	22/08/2018	24/08/2018	24/08/2018												Please Select...
48	18/LO/0712	241782	HRA Approval	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with Chronic Cough (PN027)		13			24/03/2018	27/07/2018	15/06/2018	12/07/2018	09/08/2018	09/08/2018												Please Select...
49	17/NE/0377	233847	HRA Approval	A phase 3b, multicenter, prospective, randomized, double blind, placebo-controlled study to reduce the incidence of pre-dialysis hyperkalemia with Sodium Zirconium Cyclosilicate (DIALIZE)	23/04/2018	34	27	61	10/10/2017	21/02/2018	19/02/2018	26/02/2018	27/03/2018	27/03/2018												Please Select...

Row No	REC No	IRAS No	Submission Type	Name of Trial	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	A - Permissions delaye d/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:
50	17/WS/0071	224151	HRA Approval	An International, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Dapagliflozin on the Incidence of the composite of =40% sustained reduction in eGFR, entering ESRD, CV or Renal Death in patients with Albuminuria and Moderate to Severe Renal Impairment (CKD 3-4)	11/12/2017	24	35	59	09/02/2017	13/10/2017	22/05/2017	25/10/2017	06/11/2017	06/11/2017												Please Select...
51	17/EE/0264	228153	HRA Approval	POSEIDON - A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non-Small-Cell Lung Cancer (NSCLC)	09/01/2018	1	56	57	16/06/2017	13/11/2017	12/09/2017	09/11/2017	14/11/2017	15/11/2017												Please Select...
52	16/SW/0154	204891	HRA Approval	The STAR trial: Evaluation of a care pathway for patients with long-term pain after knee replacement		31			26/06/2017	07/08/2018	04/08/2016	30/08/2018	07/09/2018	07/09/2018												Please Select...
53	17/LO/0035	218519	HRA Approval	Development and evaluation of an intervention to support Adherence to treatment in adults with Cystic Fibrosis. A randomised controlled trial and parallel process evaluation.	08/02/2018	16	36	52	20/01/2017	18/12/2017	03/04/2017	16/10/2017	03/01/2018	03/01/2018												Please Select...
54	17/EE/0311	219032	HRA Approval	Does incremental initiation of haemodialysis preserve native kidney function? A multicentre feasibility randomised control trial	30/07/2018	14	35	49	21/09/2017	11/06/2018	06/09/2017	19/06/2018	25/06/2018	25/06/2018												Please Select...
55	18/NW/0173	242176	HRA Approval	Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity and type 2 diabetes	04/07/2018	8	40	48	08/03/2018	17/05/2018	10/05/2018	11/05/2018	25/05/2018	30/05/2018												Please Select...
56	16/NW/0727	187851	HRA Approval	Multi Centre RCT of a group psychOlogical intervention for poStnatal depression in britisH mothers of south asiaN origIn - ROSHNI-2 (The word Roshni means ?light? in Urdu/Hindi)					27/04/2018	13/08/2018	06/01/2017															Please Select...
57	18/EM/0119	244650	HRA Approval	A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)		2			11/12/2017	14/08/2018	06/07/2018	09/08/2018	16/08/2018	16/08/2018												Please Select...

Row No	REC No	IRAS No	Submission Type	Name of Trial	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:
58	18/LO/0034	238090	HRA Approval	An open-label randomized, parallel-group, multicenter, observational trial to evaluate the safety and efficacy of edoxaban tosylate in children from 38 weeks gestational age to less than 18 years of age with cardiac disease at risk of thromboembolic events.		36			25/04/2018	16/08/2018	29/04/2018	11/09/2018	21/09/2018	27/09/2018												Please Select...
59	18/EM/0218	245395	HRA Approval	Upregulating the Nitric oxide pathway To Restore Autonomic Phenotype (UNTRAP). A double blind randomised first ?proof of concept? direct translational study to explore the effects of dietary nitrate supplementation on autonomic function in heart failure patients	25/09/2018	17	26	43	16/03/2018	13/08/2018	09/08/2018	30/08/2018	30/08/2018	30/08/2018												Please Select...
60	17/NE/0061	215780	HRA Approval	CONVINCE - COLchicine for preventioN of Vascular Inflammation in Non-CardioEmbolic stroke) - a randomised clinical trial of low-dose colchicine for secondary prevention after stroke.	21/03/2018	12	29	41	01/12/2017	08/02/2018	25/07/2017	15/01/2018	20/02/2018	20/02/2018												Please Select...
61	18/EM/0051	227456	HRA Approval	Testing the feasibility of a combined exercise rehabilitation programme for COPD and/or heart failure patients	30/05/2018	20	21	41	02/02/2018	19/04/2018	16/04/2018	09/05/2018	09/05/2018	09/05/2018												Please Select...
62	17/LO/0041	219676	HRA Approval	CardioMEMS OUS	22/11/2017	4	36	40	23/01/2017	13/10/2017	06/03/2017	17/08/2017	17/10/2017	17/10/2017												Please Select...
63	18/SC/0297	210470	HRA Approval	Optimal Blood sampling site (Ear Lobe or Finger Prick) for Point of Care Lactate assessment					29/03/2017	05/06/2018	13/07/2018		16/07/2018	16/07/2018												Please Select...
64	17/EM/0367	231327	HRA Approval	A multi-centre, open-label extension, safety study to describe the longterm clinical experience of mepolizumab in participants with hypereosinophilic syndrome (HES) from Study 200622	22/12/2017	18	18	36	06/09/2017	16/11/2017	10/11/2017	27/11/2017	04/12/2017	04/12/2017												Please Select...
65	17/EM/0166	222665	HRA Approval	AVAIL-T: A Phase 2a trial of Avelumab, an anti-PDL1 antibody, in relapsed and refractory peripheral T-cell lymphoma (PTCL)	08/12/2017	6	29	35	13/04/2017	03/11/2017	30/06/2017	02/11/2017	09/11/2017	09/11/2017												Please Select...
66	17/NW/0517	232120	HRA Approval	Effectiveness and cost of integrating a protocol with use of liraglutide 3.0mg into an obesity service (STRIVE Study)	28/11/2017	27	7	34	10/08/2017	25/10/2017	16/10/2017	14/11/2017	21/11/2017	21/11/2017												Please Select...
67	18/EM/0006	232310	HRA Approval	The effects of reducing prolonged sitting bouts with regular light upright movement breaks on glucose regulation in individuals at high risk of or with type 2 diabetes.	08/03/2018	19	15	34	18/07/2017	02/02/2018	31/01/2018	21/02/2018	21/02/2018	21/02/2018												Please Select...
68	17/LO/1015	223251	HRA Approval	Ankle Injury Rehabilitation - A multi-centre randomised controlled trial to assess the difference between plaster cast and functional bracing in the management of ankle fractures.	16/07/2018	1	33	34	11/09/2017	12/06/2018	04/07/2017	19/06/2018	13/06/2018	13/06/2018												Please Select...

Row No	REC No	IRAS No	Submission Type	Name of Trial	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:
69	15/NS/0113	188563	HRA Approval	The clinical and cost effectiveness of surgical interventions for stones in the lower kidney: The PUrE RCTPercutaneous Nephrolithotomy (PNL), Flexible Ureterorenoscopy (FURS) and Extracorporeal Lithotripsy (ESWL) for lower pole Kidney stones					19/04/2018	11/09/2018	09/06/2016															Please Select...
70	18/EM/1085	243153	HRA Approval	Investigating the acute effect of alternative forms of physical activity in a multi-ethnic population: The Yoga Study		27			30/04/2018	31/08/2018	16/08/2018	27/09/2018	27/09/2018	27/09/2018												Please Select...
71	17/SC/0607	217496	HRA Approval	A randomised, controlled trial of the use of a dedicated ballooned intercostal drain	14/03/2018	16	13	29	31/10/2017	13/02/2018	18/12/2017	01/03/2018	01/03/2018	01/03/2018												Please Select...
72	16/WM/0512	218042	HRA Approval	A Phase 1, open-label, randomised, repeat dose parallel group study to evaluate the pharmacokinetics, safety and tolerability of ferric maltol at three dosage levels in paediatric subjects (aged 10-17) with iron deficiency (with or without Anaemia)	11/12/2017	3	25	28	01/09/2017	13/11/2017	23/02/2017	07/11/2017	16/11/2017	16/11/2017												Please Select...
73	17/NW/0546	228365	HRA Approval	A Phase 2/3, Randomized, Open-Label Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma		7			05/12/2017	10/09/2018	05/12/2017	07/09/2018	17/09/2018	17/09/2018												Please Select...
74	17/SC/0391	227067	HRA Approval	The High-volume Haemodiafiltration vs High-flux Haemodialysis Registry Trial	19/03/2018	12	7	19	22/11/2017	28/02/2018	07/09/2017	09/02/2018	12/03/2018	13/03/2018												Please Select...
75	16/NS/0094	206213	HRA Approval	BioImpedance Spectroscopy to Maintain Renal Output: The BISTRO Trial	27/11/2017	6	12	18	15/11/2016	09/11/2017	04/10/2016	03/11/2017	15/11/2017	15/11/2017												Please Select...
76	18/LO/1301	249407	HRA Approval	VIVO Accuracy study		19			06/03/2018	13/09/2018	10/08/2018	02/10/2018	02/10/2018	02/10/2018												Please Select...
77	16/ES/0110	207747	HRA Approval	Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid					08/05/2017	18/09/2018	12/01/2017															Please Select...
78	18/SC/0155	236211	HRA Approval	A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease					20/04/2018	18/09/2018	26/04/2018															Please Select...
79	18/EM/0166	246673	HRA Approval	A double-blind, placebo-controlled study to assess the effects of inhaled PC945 in the treatment of culture-positive Aspergillus fumigatus infection in subjects with moderate to severe asthma					06/10/2017	19/09/2018	21/08/2018															Please Select...

Row No	REC No	IRAS No	Submission Type	Name of Trial	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:
80	17/EE/0361	231209	HRA Approval	A 2-treatment epoch, randomized, placebo-controlled, multicenter parallel-group study to assess the safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma	08/11/2017	0	7	7	15/09/2017	01/11/2017	31/10/2017	09/10/2017	01/11/2017	01/11/2017												Please Select...
81	18/LO/0416	235395	HRA Approval	A Phase 1b/2 Study to Evaluate Safety and Anti-tumour Activity of Avelumab in Combination with the Poly (Adenosine Diphosphate [ADP]-Ribose) Polymerase (PARP) Inhibitor Talazoparib in Patients with Locally Advanced or Metastatic Solid Tumours.		8			07/09/2017	25/09/2018	14/06/2018	25/09/2018	03/10/2018	03/10/2018												Please Select...
82	18/SC/0037	234222	HRA Approval	A Phase III, Multicenter, Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination With Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With Diffuse Large B-Cell Lymphoma (DLBCL)		2			21/10/2017	25/09/2018	16/04/2018	11/09/2018	27/09/2018	27/09/2018												Please Select...
83	17/WM/0110	212527	HRA Approval	Paediatric Hepatic International Tumour Trial					15/02/2017	25/09/2018	28/04/2017															Please Select...